Esperion Therapeutics Inc (ESPR)
2.16
-0.13
(-5.68%)
USD |
NASDAQ |
May 31, 16:00
2.16
0.00 (0.00%)
Pre-Market: 20:00
Esperion Therapeutics Free Cash Flow (Quarterly): 53.76M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 53.76M |
December 31, 2023 | -37.06M |
September 30, 2023 | -19.32M |
June 30, 2023 | -24.75M |
March 31, 2023 | -54.36M |
December 31, 2022 | -42.47M |
September 30, 2022 | -42.83M |
June 30, 2022 | -50.53M |
March 31, 2022 | -38.99M |
December 31, 2021 | -57.71M |
September 30, 2021 | -69.17M |
June 30, 2021 | -47.87M |
March 31, 2021 | -89.07M |
December 31, 2020 | -81.23M |
September 30, 2020 | -86.59M |
June 30, 2020 | 138.81M |
March 31, 2020 | -69.54M |
December 31, 2019 | -50.17M |
September 30, 2019 | -58.39M |
June 30, 2019 | -54.24M |
March 31, 2019 | 91.50M |
December 31, 2018 | -28.80M |
September 30, 2018 | -37.57M |
June 30, 2018 | -39.20M |
March 31, 2018 | -43.22M |
Date | Value |
---|---|
December 31, 2017 | -34.87M |
September 30, 2017 | -35.88M |
June 30, 2017 | -26.23M |
March 31, 2017 | -34.33M |
December 31, 2016 | -16.40M |
September 30, 2016 | -14.30M |
June 30, 2016 | -7.312M |
March 31, 2016 | -9.803M |
December 31, 2015 | -8.677M |
September 30, 2015 | -11.91M |
June 30, 2015 | -8.628M |
March 31, 2015 | -9.27M |
December 31, 2014 | -8.228M |
September 30, 2014 | -8.846M |
June 30, 2014 | -6.443M |
March 31, 2014 | -9.377M |
December 31, 2013 | -7.544M |
September 30, 2013 | -4.777M |
June 30, 2013 | -3.197M |
March 31, 2013 | -2.627M |
December 31, 2012 | -2.366M |
September 30, 2012 | -2.906M |
June 30, 2012 | -2.847M |
March 31, 2012 | -2.696M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-89.07M
Minimum
Mar 2021
138.81M
Maximum
Jun 2020
-39.09M
Average
-50.35M
Median
Free Cash Flow (Quarterly) Benchmarks
Dynavax Technologies Corp | -17.43M |
Masimo Corp | 27.00M |
United Therapeutics Corp | 338.30M |
Deciphera Pharmaceuticals Inc | -54.73M |
Ligand Pharmaceuticals Inc | 16.18M |